Associated Papers
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Elife, 2025
40238651 (PubMed )
Supplement: elife-95347-supp10.xlsx › Appendix_1-table_10
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Biorxiv : the Preprint Server for Biology, 2025
38234851 (PubMed )
Supplement: media-11.pdf
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ et al.
Nature Reviews. Clinical Oncology, 2024
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X et al.
Bmc Medicine, 2024
38281914 (PubMed )
Supplement: 12916_2024_3257_MOESM1_ESM.xlsx › Table_S4
BRAF mutations and concurrent alterations in patients with soft tissue sarcoma.
Kobayashi H et al.
Genes, Chromosomes & Cancer, 2023
Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.
Zheng L et al.
The Journal of Clinical Investigation, 2023
37053010 (PubMed )
Supplement: jci-133-165028-s194.xlsx › FH-deficient_RCC_group
The LOVD3 platform: efficient genome-wide sharing of genetic variants.
Fokkema IFAC et al.
European Journal of Human Genetics : Ejhg, 2021
34521998 (PubMed )
Supplement: 41431_2021_959_MOESM4_ESM.pdf
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Lee B et al.
Frontiers in Oncology, 2021
33777778 (PubMed )
Supplement: DataSheet_1.xlsx › Supplementary_Data_Set_1
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks.
Śmiech M et al.
Genes, 2020
Select a paper to view details